Sign In
Buy ABUS
$4.26
-0.220 (-4.91%)
At Close: Jun 02, 2026
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
10:33am, Thursday, 05'th May 2022
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
07:30am, Thursday, 21'st Apr 2022
WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus price target raised at H.C. Wainwright on upcoming data readouts
12:23pm, Monday, 14'th Mar 2022 Seeking Alpha
Arbutus Biopharma (ABUS) is trading ~4% higher in the pre-market Monday after H.C
Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
04:33pm, Monday, 07'th Mar 2022
Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022.
Arbutus Biopharma (ABUS) Q4 2021 Earnings Call Transcript
10:30pm, Thursday, 03'rd Mar 2022 The Motley Fool
ABUS earnings call for the period ending December 31, 2021.
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
07:31pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Arbutus Biopharma Corporation 2021 Q4 - Results - Earnings Call Presentation
06:47pm, Thursday, 03'rd Mar 2022 Seeking AlphaArbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
02:31pm, Thursday, 03'rd Mar 2022
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
Arbutus Biopharma GAAP EPS of -$0.83 beats by $0.03, revenue of $11M beats by $0.35M (NASDAQ:ABUS)
12:33pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Arbutus Biopharma press release (ABUS): FY GAAP EPS of -$0.83 beats by $0.03.Revenue of $11M (+59.2% Y/Y) beats by $0.35M.Shares -0.3% PM.CEO comment: “We formed strategic and…
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
12:20pm, Thursday, 03'rd Mar 2022
Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma Q4 2021 Earnings Preview
04:52pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Arbutus Biopharma (NASDAQ:ABUS) is scheduled to announce Q4 results on Thursday, Mar. 3, before market open.Consensus EPS estimate is -$0.20 and consensus revenue estimate is $2.87M.
Moderna Hijacked Technology for COVID-19 Vaccine, Lawsuit Alleges
06:49pm, Tuesday, 01'st Mar 2022 The Epoch Times
Two biotechnology companies filed a lawsuit against Moderna this week and alleged the vaccine manufacturer infringed on patented technology in the development of its commonly used COVID-19 shot. Arbutus Biopharma and Genevant Sciences, the companies, claim in a civil lawsuit that Moderna used “breakthrough technology Arbutus had already created and patented” to create the COVID-19 […]
COVID-19 patent challenges mount as Moderna faces new vaccine lawsuit
09:59pm, Monday, 28'th Feb 2022 Reuters
A lawsuit filed Monday by Arbutus Biopharma Corp against Moderna Inc is the latest in a small but growing list of high-stakes patent disputes over COVID-19 vaccines and treatments.
COVID-19 Vaccine Maker Moderna Faces Patent Infringement Suit
05:23pm, Monday, 28'th Feb 2022 IBTimes
Arbutus Biopharma Corp. and Genevant Siences allege in their complaint that Moderna infringed on patents they held to develop the COVID-19 vaccine.
Arbutus files patent infringement lawsuit against Moderna related to COVID shot
04:22pm, Monday, 28'th Feb 2022 Reuters
Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of U.S. patents related to Moderna''s COVID-19 vaccine.
